February 8th 2024
Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.
January 27th 2024
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Axitinib/Pembrolizumab Safe, Active in Untreated Kidney Cancer
February 12th 2018Combining axitinib and pembrolizumab is “safe and tolerable” among patients with previously untreated advanced renal cell carcinoma, with 73% of patients responding, according to findings from an open-label, phase Ib trial.
SM-88 Offers Promising Safety in Recurrent Localized Prostate Cancer
February 12th 2018Researchers reported promising safety data from an ongoing phase Ib/II clinical trial for SM-88, an investigational combination therapy that might one day offer an alternative to androgen deprivation therapy for men with recurrent, nonmetastatic prostate cancer.
Enzalutamide Delays Metastasis in Castration-Resistant Prostate Cancer
February 9th 2018Enzalutamide resulted in a 71% reduction in metastatic disease risk among men with castration-resistant prostate cancer and rapid prostate-specific antigen doubling time, according to the first interim analysis of data from the phase III PROSPER trial.
FDA Approves Abiraterone/Prednisone for Metastatic Prostate Cancer
February 8th 2018The US Food and Drug Administration has approved abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic prostate cancer patients with high-risk, castration-sensitive disease.
First-Line Atezolizumab/Bevacizumab Well-Tolerated in Metastatic RCC
February 5th 2018Adding atezolizumab and bevacizumab to standard care was tolerable and slowed tumor growth in patients with previously untreated clear-cell or sarcomatoid-histology metastatic renal cell carcinoma when compared to sunitinib, according to findings from a phase III study.
Apalutamide Delays Metastasis in Prostate Cancer
February 5th 2018Apalutamide was well-tolerated and associated with delayed metastasis in men with high-risk castration-resistant prostate cancer that has become refractory to conventional hormone therapy, according to an early interim analysis of the phase III SPARTAN clinical trial.
Adjuvant vs Salvage Radiotherapy in High-Risk Prostate Cancer
February 3rd 2018Adjuvant radiotherapy after prostatectomy resulted in lower rates of biochemical recurrence, distant metastases, and death compared with surveillance followed by early-salvage radiotherapy in patients with high-risk prostate cancer, according to a new study.
FDA Approves Frontline Cabozantinib for Advanced RCC
January 3rd 2018The FDA has expanded the label for cabozantinib (Cabometyx) to include first-line treatment of advanced renal cell carcinoma regardless of treatment status. Cabozantinib was initially approved in patients who had previously received anti-angiogenic therapy.
Pooled Analysis Shows Avelumab Promising in Advanced Urothelial Carcinoma
December 16th 2017The immune checkpoint inhibitor avelumab showed promising antitumor activity and a manageable toxicity profile in patients with platinum-refractory metastatic urothelial carcinoma, according to a new analysis.
Combo Antiemetic Therapy Safe, Effective for Testicular Cancer Patients on Cisplatin Chemotherapy
December 12th 2017Researchers found that combining palonosetron, aprepitant, and dexamethasone represents an effective and well-tolerated treatment to prevent CINV in testicular cancer patients receiving cisplatin.
Hypofractionated Regimen Safe, Feasible in Elderly Bladder Cancer Patients
November 8th 2017In this interview we discuss results of the HYBRID trial, which tested a hypofractionated regimen of 36 Gy over six fractions in elderly muscle-invasive bladder cancer patients who were ineligible for standard treatments.
Insurance Type, Race Tied to Disparities in Prostate Cancer
November 7th 2017Men with Medicaid are more likely to present with metastatic prostate cancer than men presenting with prostate cancer who have private insurance, according to a new study. There are racial disparities in terms of prostate cancer outcomes among those privately insured, but not among Medicaid recipients.